Media coverage about Checkpoint Therapeutics (NASDAQ:CKPT) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Checkpoint Therapeutics earned a news impact score of 0.08 on Accern’s scale. Accern also gave news headlines about the company an impact score of 48.5902632164825 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
NASDAQ:CKPT traded down $0.50 during trading hours on Thursday, hitting $4.00. The company had a trading volume of 304,547 shares, compared to its average volume of 77,110. The stock has a market cap of $134.85 million, a P/E ratio of -3.95 and a beta of 1.25. Checkpoint Therapeutics has a 52 week low of $2.22 and a 52 week high of $10.50.
Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings results on Tuesday, August 7th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.09. The business had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.37 million. Checkpoint Therapeutics had a negative net margin of 2,367.51% and a negative return on equity of 126.68%. analysts predict that Checkpoint Therapeutics will post -1.02 earnings per share for the current fiscal year.
Several analysts recently weighed in on CKPT shares. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Checkpoint Therapeutics in a report on Friday, May 11th. Zacks Investment Research cut shares of Checkpoint Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 11th.
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's products include CK-301 in Phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC); and CK-101 in the Phase 1 portion of a Phase 1/2 clinical trial for the treatment of epidermal growth factor receptor (EGFR) mutation-positive NSCLC.
Recommended Story: How to Invest in Growth Stocks
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.